{'fraction_non_alphanumeric': 0.04130162703379224, 'fraction_numerical': 0.007509386733416771, 'mean_word_length': 5.451612903225806, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Micronuclei induction by carboplatin in human lymphocyte subpopulations.

Micronuclei (MN) induction by carboplatin, cis-diammine-1,1-cyclobutane decarboxylate platinum (II) (CBDCA), in B and T lymphocytes was studied by the MAC (morphology/antibody/chromosome) method which allows the immunologic identification of different cell lineages. An increased frequency of MN in B and T lymphocytes in CBDCA-treated cultures compared with controls was observed (p < 0.001). CBD cells were found to be more sensitive to CBDCA damage. CBDCA-treated cultures showed a decrease, albeit statistically non-significant, in the proportion of CBD interphasic and mitotic cells. Furthermore, higher MN frequencies in isolated lymphocytes than in whole blood in both control and CBDCA-treated cultures were observed.